Atlas Trials

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Clinical trial NCT02414139 · COMPLETED

Trial details

NCT number
NCT02414139
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Carcinoma, Non-Small-Cell Lung
Start date
2015-06-11
Primary completion
2023-04-12
Enrollment
373

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.